Therapeutic | Tebentafusp |
Target | CD3E |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS |
Light Chain | AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | scFv Fusion |
Isotype | na |
Highest Clinical Trial (January '23) | Preregistration |
Estimated Status (January '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2017 |
INN Year Recommended | 2018 |
Companies Involved | Immunocore, MedImmune |
Conditions Approved | na |
Conditions Active | Malignant melanoma, Uveal melanoma |
Conditions Discontinued | na |
Notes | T-Beta section specific for PMEL peptide 280-288 presented by MH1 |
SAbDab papers
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]
Thera-SAbDab paper
Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]